SHAREHOLDER ALERT: Rigrodsky Law, PA Is Exploring Acquisition of Revance Therapeutics, Inc.

Wilmington, Delaware–(Newsfile Corp. – August 13, 2024) – Rigrodsky Law, PA is investigating Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC) for possible breaches of fiduciary duty and other violations of law relating to Revance’s agreement to be acquired by Crown Laboratories, Inc. Under the terms of the agreement, Revance shareholders will receive $6.66 per share in cash.

For more information about this investigation and your rights, please visit: https://www.rl-legal.com/cases-revance-therapeutics-inc.